Noted investment personality Jim Cramer has given his approval to pharmaceutical company Zoetis (NYSE:ZTS), stating he likes it very much. In the meantime, the Public Sector Pension Investment Board and APG Asset Management have both increased their holdings in the company, with MBB Public Markets further investing $5.54 million. Zoetis has also formed a strategic partnership with Danone to explore sustainable innovations in dairy farming. Despite some dips in stock price, investors remain positive, with an analysis revealing it has consistent earnings growth. Moreover, if one had invested $1000 in Zoetis a decade ago, their investment would have grown significantly. Nonetheless, some alarming reports suggest Zoetis' arthritis drugs may have harmful effects on pets. The company has increased its revenue growth guidance and authorised a $6 billion share repurchase program. Despite some safety concerns, Zoetis continues to be a promising investment in the eyes of many, with strong demand for its pet treatments leading to an elevated financial forecast for 2024.
Zoetis ZTS News Analytics from Tue, 13 Feb 2024 08:00:00 GMT to Sun, 29 Sep 2024 08:42:55 GMT - Rating 6 - Innovation 4 - Information 4 - Rumor -2
